Objective: Exogenously administered CO interferes with PMN recruitment to the inflamed organs. The mechanisms of COdependent modulation of vascular proadhesive phenotype, a key step in PMN recruitment, are unclear. Methods: We assessed the effects/mechanisms of CO liberated from a water-soluble CORM-3 on modulation of the proadhesive phenotype in hCMEC/D3 in an in vitro model of endotoxemia. To this end, hCMEC/D3 were stimulated with LPS (1 lg/mL) for six hours. In some experiments hCMEC/D3 were pretreated with CORM-3 (200 lmol/L) before LPS-stimulation. PMN rolling/ adhesion to hCMEC/D3 were assessed under conditions of laminar shear stress (0.7 dyn/cm 2 ). In parallel, expression of adhesion molecules E-selectin, ICAM-1, and VCAM-1 (qPCR), activation of transcription factors, NF-jB and AP-1 (ELISA), and MAPKsignaling (expression/phosphorylation of p38, ERK1/2, and JNK1/ 2; western blot) were assessed. Results: The obtained results indicate that CORM-3 pretreatment reduces PMN rolling/adhesion to LPS-stimulated hCMEC/D3 (p < 0.05). Decreased PMN rolling/adhesion to hCMEC/D3 was associated with CORM-3-dependent inhibition of MAPK JNK1/2 activation (Tyr-phosphorylation), inhibition of transcription factor, AP-1 (c-Jun phosphorylation), and subsequent suppression of VCAM-1 expression (p < 0.05).
INTRODUCTION
Severe sepsis is a leading killer of patients in intensive care units with an estimated mortality of 45% [24] . Brain dysfunction associated with severe sepsis is termed SAE; coma related to SAE is an independent predictor of death in severe sepsis [12, 39, 51] . A possible contributor to SAE is inflammation instigated by circulating bacterial products (e.g., LPS) that affect the cerebrovascular endothelium of the BBB.
One of the key features of severe sepsis is an overwhelming recruitment of PMN to the affected organs [34] . PMN recruitment to the brain, however, is minimized due to presence of the BBB and higher shear stress in the brain DOI:10.1111/micc.12161
Original Article circulation under euvolemic conditions [21] . However, CPP in septic patients is decreased and CBF is reduced independent of changes in either blood pressure or cardiac output [1] . Septic patients are typically intravascularly depleted and experience lower shear stress in the brain microcirculation due to decreased driving pressure, thus potentially exacerbating leukocyte-endothelial cell interaction. In experimental models, challenging the cerebrovascular endothelium with sepsis-relevant stimulus(i) upregulates proadhesive phenotype resulting in increased interaction (e.g., rolling/adhesion) with circulating PMN [58] . The latter interactions may further activate cerebrovascular endothelium and contribute to the BBB dysfunction. Indeed, PMN recruitment to the brain perivascular space and formation of the perivascular edema has been demonstrated in sepsis animal models [9, 58, 59] . Therefore, targeting leukocyte-endothelial cell adhesive interactions during early onsets of sepsis is an attractive therapeutic approach to suppress/prevent SAE.
Endogenously produced CO (as a product of heme oxygenase-1, HO-1, activity) is recognized as a signaling molecule with potent anti-inflammatory effects [28] . However, therapeutic use of inhaled CO is limited due to potential formation of COHb to toxic levels [13] . Recently, CORMs [transition metal carbonyls capable of carrying/ releasing CO] were synthesized and demonstrated beneficial effects in suppressing/preventing inflammatory response(s) in various tissues employing both in vitro and in vivo experimental approaches [3, 7, 14, 28] . Importantly, the beneficial effects of systemically administered CORMs are achieved without increasing COHb to toxic levels [10, 28, 29, 31, 19] .
Recent findings indicate that anti-inflammatory effects of CORMs are largely attributed to their ability to suppress the leukocyte (e.g., PMN) proadhesive/promigratory phenotype resulting in reduced PMN recruitment and suppression of sepsis-relevant inflammation [3, 26, 54] . However, the ability of CORMs (in particular, water-soluble CORM-3) to modulate vascular endothelial cell inflammatory activation/dysfunction is controversial and requires further investigation. Moreover, no studies to date investigated CORM-dependent modulation of PMN interaction with human CVECs.
Therefore, in this study we assessed CORM-3-dependent modulation of hCMEC/D3 [55] proadhesive phenotype and subsequent adhesive interactions (e.g., rolling/adhesion) with human-derived PMN under experimental conditions of flow in an in vitro model of acute endotoxemia.
MATERIALS AND METHODS

Ethics
The study was approved by the Office of Research Ethics at Western University (London, Ontario, Canada).
Cell Culture
hCMEC/D3 represent a stable, fully characterized, and welldifferentiated human brain endothelial cell line [55] . hCMEC/ D3 were kindly provided by Dr 
PMN Rolling/Adhesion Assay
PMN-hCMEC/D3 adhesive interactions (i.e., rolling/adhesion) were assessed employing parallel flow perfusion slides (l-Slide IV 0.4 ; [11] ) and using 0.7 dyn/cm 2 laminar fluid shear stress to mimic pathophysiological (i.e., hypoperfused) status of the brain microcirculation [15, 26, 36] . To this end, hCMEC/D3 were grown in the l-Slide IV 0.4 channels for 48 hours and pretreated/stimulated with CORM-3/LPS, respectively. Subsequently, the slides were transferred and mounted on to inverted microscope (DIAPHOT 300, Nikon) equipped with the air-heated (37°C) chamber. l-Slide IV 0.4 channels containing hCMEC/D3 were connected to the syringe pump (Harvard Apparatus 22) and perfused with the cell culture medium for five minutes. Subsequently, human- . Dilution curves of representative cDNA samples were used to determine conditions resulting in 95-105% amplification efficiency which were subsequently used for experimental samples. qPCR was carried out on a CFX96 Real-Time System â (Bio-Rad) using an initial 95°C incubation for 30 seconds and 40 cycles of: five seconds at 95°C and 15 seconds at 60°C. Relative expression values were determined by normalization to GAPDH and 18 seconds using Bio-Rad CFX Manager v 3.1 Gene Study application and the mean target stability values for the reference genes were determined to be M < 0.5. For statistics, the mean expression, SEM and n value were imported into GraphPad Prism 4.03 (La Jolla, CA, USA) and analyzed using one-way ANOVA on each gene. Results were considered significant when p < 0.05.
Western Blot
hCMEC/D3 were grown in six-well cell culture plates (BD Falcon, Mississauga, ON, Canada) and pretreated/stimulated with CORM-3/LPS, respectively. Subsequently, the cells were washed with PBS and lysed in a hot 2X concentrated sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample-loading buffer. Total cellular proteins were resolved on 8% SDS-PAGE and transferred to polyvinylidene difluoride membranes as described elsewhere. The membranes were blocked for one hour in 5% skim milk and 0.1% Tween 20 (Sigma-Aldrich) and incubated for one hour with primary antibodies directed against phosphorylated-p38 (phospho-p38: ab32557), ERK (phospho-ERK: ab50011), JNK1/2 (phospho-JNK1/2: ab4821) MAPK, respectively. For protein loading, control membranes were probed with mouse monoclonal antibody against GAPDH (ab8245). All primary antibodies were purchased from Abcam Inc. (Toronto, ON, Canada). Protein bands were visualized employing secondary horse radish peroxidase-conjugated anti-mouse (#616520; Invitrogen, Burlington, ON, Canada) or anti-rabbit (#656120; Invitrogen) antibody and enhanced chemiluminescence approach. Band intensities were captured using a MicroChemi imaging system (Froggabio, Toronto, Canada) and quantified using GelQuant Pro Software (FroggaBio).
ELISA Assays for NF-jB and AP-1 (c-Jun) Activation
hCMEC/D3 were grown in six-well plates for 48 hours and pretreated with either CORM-3 or iCORM-3 for two hours. Subsequently, the cells were stimulated with LPS (1 lg/mL) for one hour and processed for assessment of NF-jB activation. In parallel, cells were stimulated with LPS for 30 min and collected for assessment of AP-1 activation. In each ELISA assay, PathScan Phospho-NF-jB p65 (Ser536) Sandwich ELISA Kit (#7173) and PathScan Phospho-c-Jun (Ser63) Sandwich ELISA Kit II (#7145) (both from Cell Signaling Technology) were used in accordance to the manufacturer's instruction. The ELISA reactions were read at 450 nm wavelengths using microplate reader (Bio-Rad, model 680).
Statistical Analysis
Statistical analyses were performed with StatMate IV and data are presented as mean AE SE for the indicated number of separate experiments. All analyses were based on more than four separate experiments. Differences between groups were determined by analysis of variance (ANOVA) and Tukey's correction. p-value of less than 0.05 was considered statistically significant.
RESULTS
PMN Rolling/Adhesion Assay
Stimulation of hCMEC/D3 with LPS (1 lg/mL) for six hours resulted in an increase in PMN rolling and adhesion in the presence of fluid shear stress ( Figure 1 ). Pretreatment of hCMEC/D3 with CORM-3 effectively suppressed both LPSinduced PMN rolling and adhesion to hCMEC/D3. In these experiments, CORM-3 reduced PMN rolling by 54. 
Adhesion Molecule Expression
To test whether CORM-3-pretreatment suppressed PMN rolling/adhesion to LPS-stimulated hCMEC/D3 is a consequence of CORM-3-dependent modulation of hCMEC/D3 proadhesive phenotype (e.g., reduced levels of cell adhesion molecule expression), hCMEC/D3 were analyzed for expression of E-selectin, ICAM-1, and VCAM-1 employing a qPCR approach. Stimulation of hCMEC/D3 with LPS resulted in upregulation of E-selectin, ICAM-1, and VCAM-1 expression (Figure 2A-C) . Pretreatment of hCMEC/D3 with CORM-3 but not with iCORM-3 effectively suppressed expression of VCAM-1 (p < 0.05) ( Figure 2C ), however, failed to reduce LPS-induced expression of E-selectin and ICAM-1 (Figure 2A,B) .
NF-jB and AP-1 Activation
Next, we assessed the effects of CORM-3-derived CO on modulation of two key inflammation-relevant transcription factors, NF-jB and AP-1, involved in upregulation of the adhesion molecule expression in numerous models of inflammation [23, 56] . Stimulation of hCMEC/D3 with LPS-induced activation of AP-1 as evidenced by the increase in c-Jun Ser63-phosphorylation levels (p < 0.05) (Figure 3) . Pretreatment of hCMEC/D3 with CORM-3 effectively suppressed LPS-induced activation of AP-1 (p < 0.05) (Figure 3) , however, failed to interfere with LPS-induced activation of NF-jB, as assessed by LPS-induced changes in p65 p-Ser536 levels ( Figure 4) . In both experiments iCORM-3 had no effect neither on LPS-induced phosphorylation levels of AP-1 nor NF-jB ( Figures 3 and 4 , respectively).
MAPK Activation
MAPKs participate in LPS-induced signal transduction and play a key role in activation of AP-1 [5, 57] . Therefore, we assessed whether CORM-3-derived CO can modulate MAPK p38, ERK1/2, and JNK1/2 activation following stimulation with LPS. Pretreatment of hCMEC/D3 with CORM-3 (but Figure 5 ). In contrast, CORM-3 failed to suppress LPS-induced phosphorylation of p38 and ERK1/2 (data not shown).
To further delineate the role of JNK1/2 signaling in modulation of the proadhesive/proinflammatory phenotype in hCMEC/D3, parallel experiments were performed employing selective JNK inhibitor, SU3327. Pretreatment of hCMEC/D3 with SU3327 (25 nM) in a similar manner as CORM-3, effectively reduced LPS-induced PMN rolling/ adhesion to hCMEC/D3 ( Figure 6A ), prevented activation of AP-1 ( Figure 6B ), and significantly reduced expression of VCAM-1 ( Figure 6C ).
DISCUSSION
The BBB represents a complex and unique structure of the brain microcirculation with the luminal blood vessel comprised of CVECs. During severe sepsis, systemic inflammation likely subjects CVECs to the circulating proinflammatory mediators (e.g., LPS and cytokines) resulting in a subsequent upregulation of the CVEC proinflammatory phenotype [4, 41] . In addition, due to decreased CPP and reduced CBF observed in septic patients [1] , CVECs are likely exposed to the critical paracellular effects of rolling/adherent PMNs. The current study was designed to assess CORM-3-dependent modulation of LPS-induced inflammatory responses in hCMEC/D3 cells, representing consistent and well-characterized model of human brain microvascular endothelium in vitro [36, 55] .
Recent studies in the field indicate that CO, a natural end product of HO activity in mammalian tissues exhibits potent anti-inflammatory effects [30, 38, 47] . Inhaled CO (200-500 ppm) reduces inflammation and organ dysfunction not only in animal models but also in humans with lung inflammation and kidney transplantation (Phase I and II clinical trials) [30] . Nevertheless the use of inhaled CO is hampered by a rapid formation of toxic levels (>15%) of HbCO resulting in decreased oxygen transport to tissues [10, 45, 46] . Recently, transitional metal carbonyls, CORMs, have been developed for delivery of CO in a controlled manner that allows initial bypassing of the pulmonary circulation, and having no or only moderate effects on HbCO formation (<3-5% HbCO) [10, 28, 29, 31] . It has been demonstrated that CORM-derived CO offers antiapoptotic, antiatherosclerotic, and anti-inflammatory effects in animal models of inflammation/injury such as ischemia/reperfusion [14, 16] , pulmonary hypertension [60] , transplantation [2, 48, 50] , compartment syndrome [19] , and sepsis/endotoxemia [3, 6, 26] . In addition, survival of septic (i.e., LPS-challenged) mice was markedly improved in animals that have been pretreated and subsequently exposed to CO before/during induction of endotoxemia [27] .
The exact mechanism(s) of CO-dependent modulation of inflammatory responses are largely unknown and often controversial. Research aimed at understanding the mechanisms of CO-mediated cell/organ protection suggests the role of guanylate cyclase [33] , MAPK [37] , PI3K, and NF-jB signaling pathways [3, 17] . Hence, the actions mediated by CO seem to invoke unique stimulus-dependent signaling mechanism(s) in various cell types.
Despite of the complexity associated to CO-mediated cell signaling recent evidence indicate that anti-inflammatory effects of CORMs are largely attributed to their ability to suppress leukocyte-endothelial cell adhesive interaction resulting in reduced leukocyte recruitment to the affected organs [3, 26, 52, 54] .
PMN recruitment to the inflamed tissues involves a series of complex, yet well coordinated PMN-EC adhesive interactions (i.e., PMN rolling and firm adhesion) and migration across the endothelial barrier within the microvasculature [20] . The current literature indicates that there is a general consensus on the molecular determinants of PMN-EC adhesive interactions, i.e., extensive characterization of the adhesion molecules (e.g., P-selectin, E-selectin, ICAM-1, and VCAM-1 on the vascular endothelium) and their ligands (e.g., L-selectin, sialyl Lewis X, and b2-and b1-integrins on PMNs), the kinetics of their expression after an induction with various proinflammatory mediators (e.g., tumor necrosis factor-alpha [TNF-a] or LPS), and their relative roles in rolling and the development of strong adhesive interactions [20, 22, 42, 43] .
With regard to the above, dimethyl sulfoxide (DMSO)-soluble CO-releasing molecule, CORM-2, and water-soluble, CORM-3, interfere with leukocyte accumulation in the liver of septic mice [3] and skeletal muscle of compartment syndrome-challenged mice [19] , respectively. In addition, it has been demonstrated that water-soluble CORM-3 suppresses PMN-HUVEC adhesive interaction by reducing CD11b (a M b 2 -integrin) and L-selectin surface levels in platelet activating factor-stimulated PMN [54] . Similarly, our previous findings also demonstrated that CORM-3 inhibits PMN accumulation in the septic lung and suppresses LPS/FormylMethionyl-Leucyl-Phenylalanine-induced PMN migration across HUVEC monolayer through a mechanism that requires initial PMN activation (i.e., increased O 2 À production) and subsequent downregulation of PMN cell-surface levels of serine protease, elastase [26] . Moreover, our recent findings indicate that CORM-3 very effectively interferes with the neutrophilic MPO activity and, in turn, suppresses MPOinduced endothelial cell (HUVEC) activation (e.g., oxidative stress) and dysfunction (e.g., permeability) [37] . Taken together, these findings indicate that CORMs significantly reduce the overall inflammatory potential of PMN, and, therefore, interfere with the leukocyte (e.g., PMN)-dependent propagation of the inflammatory response. CORM-dependent modulation of endothelial cell inflammatory activation/dysfunction, however remains poorly investigated and is quite controversial. In this regard, the findings of our current study indicate that CORM-3 is effective in suppressing VCAM-1 but not ICAM-1 or Eselectin adhesion molecule expression (Figure 2 ). These findings are consistent with the previous study by Urquhard et al. [54] demonstrating that CORM-3 fails to suppress ICAM-1 and E-selectin expression in TNF-a-stimulated endothelial cells (HUVEC). On the contrary, the study by Song et al. [49] demonstrated the efficacy of CORM-3 in inhibition of E-selectin and VCAM-1 expression in TNF-astimulated HUVEC. In addition, it has been shown that CORM-2 (a DMSO-soluble CORM) reduces high-glucoseinduced expression of ICAM-1 in HUVEC [35] . Moreover, CORM-2 appears to be very effective in reducing tissue levels of ICAM-1 in septic liver and suppressing reactive oxygen species production, NF-jB activation, and subsequent NFjB-dependent expression of ICAM-1, resulting in overall reduced adhesion of PMN to LPS-stimulated HUVEC [3] .
The discrepancies reported with CORMs may lay in different experimental approaches employed, e.g., measuring adhesion molecule levels in the tissue [3, 52] vs cell culture [49, 54] ; using western blot [3, 52] vs flow cytometry [49, 54] vs cell ELISA [3] ; nature and duration of inflammatory stimulation (e.g., TNF-a [49, 54] vs LPS [3] ); and use of different CO donors (e.g., CORM-2 [3, 35, 52] vs CORM-3 [49, 54] ) and various concentrations of CORMs (e.g., 10-1000 lM [3, 49, 54] ). In addition, endothelial cells obtained from different vascular beds (e.g., HUVEC representing the large blood vessels vs hCMEC/D3, representing brain microvascular endothelial cells) may display different levels of adhesion molecule expression and/or sensitivity to CORMs, as well. Finally, differences in treating the cells/tissues with CORMs (e.g., pretreatment with CORMs before stimulation vs cotreatment with CORMs during stimulation vs posttreatment with CORMs after stimulation) may also result in different experimental outcomes. With regard to the latter, our current study indicates that administration of CORM-3 to hCMEC/D3 during stimulation with LPS (cotreatment approach) failed to significantly suppress LPS-induced upregulation of the proadhesive phenotype (data not shown).
Despite obvious complexity in CO-mediated cell protection our current findings indicate that pretreatment of hCMEC/D3 with CORM-3 preferentially interferes with JNK1/2-signaling and subsequent activation of AP-1 (but not NF-jB) resulting in suppressed hCMEC/D3 proadhesive phenotype. These findings are consistent with the previously published results indicating CO-mediated inhibition of JNK signaling and subsequent selective suppression of one of the major inflammation-relevant transcription factors, AP-1 (cJun/c-Fos), but not NF-jB, resulting in reduced production of IL-6 and IL-1b by LPS-stimulated macrophages [27] . Both AP-1 and NF-jB transcription factors are well known for their role in upregulation of the proinflammatory cytokine and adhesion molecule expression [4, 44] . MAP kinases (e.g., JNK), on the other hand, are critical for transducing LPSinduced inflammatory signaling that activates AP-1 in various cells (e.g., endothelial cells and macrophages) [8, 18, 27, 37] . Relevant to this study, CO-dependent inhibition of LPS/tolllike receptor-signaling has also been demonstrated [32] .
The inability of CORM-3 (as oppose to CORM-2 [3] ) in the current study to interfere with LPS-induced activation of NF-jB in hCMEC/D3 requires further investigation, however, may explain at least in part why CORM-3 failed to suppress LPS-induced expression of E-selectin and ICAM-1 (molecules which expression is primarily controlled by NFjB activation). On the other hand, under experimental conditions employed in the current study CORM-3-dependent inhibition of JNK signaling appears to be responsible for the suppression of AP-1 transcription factor that along with NF-jB plays a critical role in LPS-induced upregulation of adhesion molecule (e.g., VCAM-1) expression [40, 53] . Our current findings favor the latter scenario and indicate that CORM-3-derived CO acts in a similar manner as JNK inhibitors (i.e., SU3327) by suppressing LPS-induced expression of VCAM-1 and resulting in a subsequent reduction in PMN adhesion to hCMEC/D3.
Thus, the unique finding of our study is that CORM-3-suppressed VCAM-1 expression to effectively inhibit neutrophilic leukocyte (PMN) adhesion. In addition, our findings indicate a potential role for VCAM-1 as a prime molecule involved in PMN rolling upon activated cerebrovascular endothelium. Whether CORM-3 preferentially regulates PMN adhesive interactions with CVECs through VCAM-1-dependent mechanism, or also as a consequence of CORM-3-dependent modulation of E-selectin affinity remains to be determined.
In summary, our findings are the first to demonstrate the efficacy of CORM-3 pretreatment in suppressing sepsisrelevant activation (e.g., upregulation of the proadhesive phenotype) of human-derived CVECs in vitro through a mechanism involving JNK/AP-1 signaling.
PERSPECTIVE
Inflammatory activation of cerebrovascular endothelium contributes to the impaired function of the BBB. We demonstrate that increased human cerebrovascular endothelial cell activation and proadhesive phenotype (i.e., expression of VCAM-1) following stimulation with bacterial LPS are suppressed by water-soluble CORM-3. These findings indicate potential therapeutic applicability of CORMs in preventing inflammatory activation of the vascular endothelium.
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